Related Experiment Video

Updated: Jun 25, 2026

Cell-Based Drug Screening for Inhibitors of Autophagy Related 4B Cysteine Peptidase
09:51

Cell-Based Drug Screening for Inhibitors of Autophagy Related 4B Cysteine Peptidase

Published on: June 30, 2023

Autophagy pathways in glioblastoma

Hong Jiang1, Erin J White, Charles Conrad

  • 1Department of Neuro-Oncology, University of Texas M D Anderson Cancer Center, Houston, Texas, USA.

Methods in Enzymology
|February 17, 2009
PubMed

Insights

Glioma cells respond better to autophagy than apoptosis. Autophagy is a promising mechanism for developing new glioma therapies, with methods to study it detailed for clinical trials.

Area of Science:

  • Oncology
  • Cell Biology
  • Molecular Biology

Background:

  • Glioma cells exhibit differential responses to therapeutic interventions, favoring autophagy over apoptosis.
  • Key glioma chemotherapies like temozolomide and rapamycin, along with emerging oncolytic adenoviruses, are known to induce autophagy.
  • Autophagy represents a significant and promising mechanism for novel glioma treatment strategies.

Purpose of the Study:

  • To present comprehensive methods for studying autophagy in glioma cells.
  • To explore the utility of autophagy markers for monitoring therapeutic efficacy in clinical trials.
  • To discuss challenges and future directions in glioma autophagy research.

Main Methods:

  • In vitro assessment of cellular markers: acidic vesicle organelles and GFP-LC3 punctation.
  • Biochemical analysis: LC3-I/II conversion, p62 degradation, Atg12-Atg5 accumulation, and p70S6K dephosphorylation.
  • Ultrastructural examination of autophagosomes and immunostaining for LC3B and Atg5 in treated tumors.

Main Results:

  • Established methods allow for detailed in vitro and in vivo study of autophagy in gliomas.
  • LC3B and Atg5 up-regulation can be assessed via immunostaining, indicating therapeutic response.
  • Autophagy markers show potential as surrogate endpoints for clinical trials.

Conclusions:

  • Autophagy is a critical pathway in glioma cell response to therapy.
  • Standardized methods for studying autophagy are essential for advancing glioma treatment.
  • Autophagy markers hold promise for monitoring treatment effectiveness in clinical settings.

Related Concept Videos

Delivery Pathways to the Lysosome01:36

Delivery Pathways to the Lysosome

Eukaryotic cells use different mechanisms to eliminate toxic waste obsolete and worn-out substances. Lysosomes play a pivotal role in this, and hence, these substances are carried to the lysosome from other parts of the cell and extracellular space through different pathways. The most elaborately studied pathways to the lysosome are the endocytic pathways.
Endocytosis
In endocytosis, the cell membrane takes up macromolecules and particles from the surrounding medium. Clathrin-mediated...
Autophagy01:27

Autophagy

Autophagy is a self-digesting process by which a cell protects itself from threats both within and outside the cell, ranging from abnormal proteins to invading bacteria. In this process, obsolete components of the cell and invading microbes are degraded by hydrolytic enzymes active in an acidic environment of the lysosomal lumen.
An autophagic pathway consists of a series of signaling events activated in response to diverse stress and physiological conditions such as food deprivation,...
Autophagic Cell Death01:18

Autophagic Cell Death

Christian de Duve discovered “autophagy,” a process in which cellular components are engulfed by membrane-bound organelles called autophagosomes. The autophagosomes then fuse with lysosomes to digest the enclosed contents. Autophagy is generally activated in cells to prevent cell death. However, cell death is triggered when the damage is beyond repair.
Autophagy and Apoptosis
Autophagy can activate apoptosis. In normal conditions, the autophagy activating protein Beclin-1 and pro-apoptotic...
Cellular Injury V: Apoptosis and Autophagy01:22

Cellular Injury V: Apoptosis and Autophagy

Cells respond to damage and stress through highly coordinated processes that decide whether they survive or undergo controlled self-destruction. Two major pathways involved in this regulation are apoptosis, a type of programmed cell death, and autophagy, a survival mechanism that helps cells adapt to adverse conditions.ApoptosisApoptosis removes aged or injured cells to maintain tissue balance. During this process, the cell shrinks, chromatin condenses and fragments, and membrane-bound...
The Intrinsic Apoptotic Pathway01:31

The Intrinsic Apoptotic Pathway

Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...